These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22682141)

  • 1. Accounting for death as a competing risk in cancer-associated thrombosis studies.
    Campigotto F; Neuberg D; Zwicker JI
    Thromb Res; 2012 Apr; 129 Suppl 1():S85-7. PubMed ID: 22682141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk assessment for cancer-associated thrombosis: what is the best approach?
    Khorana AA
    Thromb Res; 2012 Apr; 129 Suppl 1():S10-5. PubMed ID: 22682117
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Competing events in patients with malignant disease who are at risk for recurrent venous thromboembolism.
    Parpia S; Julian JA; Thabane L; Lee AY; Rickles FR; Levine MN
    Contemp Clin Trials; 2011 Nov; 32(6):829-33. PubMed ID: 21777700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of venous thromboembolism and primary prophylaxis in cancer. Should all patients receive thromboprophylaxis?
    Pabinger I; Ay C
    Hamostaseologie; 2012; 32(2):132-7. PubMed ID: 21822526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Venous thromboembolism in patients with colorectal cancer: incidence and effect on survival.
    Alcalay A; Wun T; Khatri V; Chew HK; Harvey D; Zhou H; White RH
    J Clin Oncol; 2006 Mar; 24(7):1112-8. PubMed ID: 16505431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epidemiology, risk and outcomes of venous thromboembolism in cancer.
    Falanga A; Russo L
    Hamostaseologie; 2012; 32(2):115-25. PubMed ID: 21971578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cumulative incidence in competing risks data and competing risks regression analysis.
    Kim HT
    Clin Cancer Res; 2007 Jan; 13(2 Pt 1):559-65. PubMed ID: 17255278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-molecular-weight heparin and survival in lung cancer.
    Noble S
    Thromb Res; 2012 Apr; 129 Suppl 1():S114-8. PubMed ID: 22682120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Venous thromboembolism in ovarian cancer.
    Rodriguez AO; Wun T; Chew H; Zhou H; Harvey D; White RH
    Gynecol Oncol; 2007 Jun; 105(3):784-90. PubMed ID: 17408726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and initial treatment of venous thromboembolism in patients with cancer.
    Streiff MB
    J Clin Oncol; 2009 Oct; 27(29):4889-94. PubMed ID: 19738109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing risks analysis of patients with osteosarcoma: a comparison of four different approaches.
    Tai BC; Machin D; White I; Gebski V;
    Stat Med; 2001 Mar; 20(5):661-84. PubMed ID: 11241570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer-associated thrombosis: risk factors, candidate biomarkers and a risk model.
    Sud R; Khorana AA
    Thromb Res; 2009; 123 Suppl 4():S18-21. PubMed ID: 19303497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Venous thromboembolism (VTE) in patients with cancer: epidemiology and risk factors.
    Wun T; White RH
    Cancer Invest; 2009; 27 Suppl 1():63-74. PubMed ID: 19291526
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer-associated thrombosis.
    Sood SL
    Curr Opin Hematol; 2009 Sep; 16(5):378-85. PubMed ID: 19606029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of fibrinogen plasma levels, the -455G>A fibrinogen and the factor XIII A subunit (FXIII-A) Val34Leu polymorphism in cancer-associated venous thrombosis.
    Tiedje V; Dunkler D; Ay C; Horvath B; Quehenberger P; Pabinger M; Zielinski C; Pabinger I; Mannhalter C
    Thromb Haemost; 2011 Nov; 106(5):908-13. PubMed ID: 21901234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival analysis in total joint replacement: an alternative method of accounting for the presence of competing risk.
    Fennema P; Lubsen J
    J Bone Joint Surg Br; 2010 May; 92(5):701-6. PubMed ID: 20436009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study.
    Ay C; Vormittag R; Dunkler D; Simanek R; Chiriac AL; Drach J; Quehenberger P; Wagner O; Zielinski C; Pabinger I
    J Clin Oncol; 2009 Sep; 27(25):4124-9. PubMed ID: 19636003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The NCCN Clinical Practice Guidelines on Venous Thromboembolic Disease: strategies for improving VTE prophylaxis in hospitalized cancer patients.
    Khorana AA
    Oncologist; 2007 Nov; 12(11):1361-70. PubMed ID: 18055857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Venous thrombosis in patients with solid tumors: determination of frequency and characteristics.
    Sallah S; Wan JY; Nguyen NP
    Thromb Haemost; 2002 Apr; 87(4):575-9. PubMed ID: 12008937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recurrent venous thromboembolism after pregnancy-associated versus unprovoked thromboembolism.
    White RH; Chan WS; Zhou H; Ginsberg JS
    Thromb Haemost; 2008 Aug; 100(2):246-52. PubMed ID: 18690344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.